Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328697 | 0.72 | — | — | |
| SCHEMBL10917072 | 0.70 | CRHBP (0.35) | RAD52KDM4ERAB9ASMN1; SMN2QRFPR | |
| SCHEMBL558033 | 0.70 | — | — | |
| SCHEMBL130245 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL28160401 | 0.68 | NOS3 (0.46) | NOS3NOS1NOS2NUDT1 | |
| Hydrochloric Acid SCHEMBL27632604 | 0.68 | NOS3 (0.46) | NOS3NOS1NOS2NUDT1 | |
| Ammonia Solution, Strong SCHEMBL5132889 | 0.68 | NOS3 (0.46) | NOS3NOS1NOS2NUDT1 | |
| Ammonia Solution, Strong SCHEMBL15795891 | 0.67 | NOS3 (0.39) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL19979074 | 0.67 | NOS3 (0.39) | NOS3NOS1NOS2NUDT1KDM4E | |
| SCHEMBL10517407 | 0.65 | KDM4E (0.40) | NOS3NOS1NOS2NUDT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | claimed |
| US-6689777-B2 | DEPOLYMERIZING HEMOZOIN USING 2-IMINO-NAPHTHO(1,2-D)THIAZOL-5-OL DERIVATIVES | KENNETH S. WARREN INSTITUTE | 2004-02-10 | — | — | US | disclosed |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | TYR, CRYZ, RHOT2 | NOS3 825/4885NOS1 2058/4885NOS2 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.